Acetaminophen Risk Management On Tap For Joint Advisory Panel
This article was originally published in The Tan Sheet
Executive Summary
FDA is looking for risk-management solutions to liver problems linked to the misuse of acetaminophen in OTC and prescription products, and will convene a joint advisory panel to discuss potential steps to take
You may also be interested in...
Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data
A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks
Firms Must Pair Education With Mechanical Constraints To Reduce Overdoses
Manufacturers must "engineer" safety constraints into acetaminophen products to reduce the risk of overdose and liver damage because consumer education alone is not enough, a joint FDA advisory committee said June 30
Acetaminophen Proposals Could Hit Firms Hard Via Sales And Costs
Acetaminophen product manufacturers stand to incur huge costs and reduced revenue opportunities if FDA implements a working group's recommendations to reduce hepatotoxicity risk